{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:56:06Z","timestamp":1781938566134,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormone receptor-positive (HR+), human epithelial growth factor receptor 2 (HER2) overexpressed breast cancer (BC) represents the more aggressive subtype of HR\u2009+\u2009BC, typically associated with poor clinical outcomes. Despite significant advancements in the treatment of estrogen receptor-positive (ER+)\/HER2\u2009+\u2009BC, resistance to endocrine therapy (ET) poses a continued challenge. Imlunestrant is a next-generation, oral, brain-penetrant, pure antagonistic ER degrader designed to deliver continuous ER target inhibition. It has shown favorable clinical benefit, safety, and pharmacokinetics (PK) when used as monotherapy or with targeted therapy in patients with ER+\/HER2- advanced BC (ABC). Here, we present the safety and efficacy of imlunestrant with HER2 targeted therapy in patients with ER+\/HER2\u2009+\u2009ABC of the EMBER trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized to imlunestrant (400\u00a0mg RP2D)\u2009+\u2009trastuzumab (group A) versus imlunestrant\u2009+\u2009trastuzumab\u2009\u00b1\u2009abemaciclib [(150\u00a0mg twice daily) group B] or received maintenance treatment with imlunestrant\u2009+\u2009trastuzumab\u2009+\u2009pertuzumab until progression or discontinuation at standard doses (group C). In the randomized allocation, eligible patients with locally advanced or metastastic disease had received\u2009\u2265\u20092 prior HER2-directed regimens in the metastatic setting, and no prior treatment with CDK4\/6 inhibitors or fulvestrant. The maintenance cohort (group C) was added later to include patients without disease progression after first-line induction taxane-based chemotherapy (any duration), trastuzumab, and pertuzumab. Endpoints included safety, PK, antitumor activity, and tumor biomarker assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 45 patients with ER+\/HER2\u2009+\u2009ABC were treated (group A,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918; group B,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921; group C,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096). Adverse events were consistent with the known safety profiles of the partner drugs. Imlunestrant PK was consistent with previously reported data. For groups A, B, and C, the objective response rates (ORRs) were 7%, 25%, and 33%, respectively, while the clinical benefit rates (CBRs) were 44%, 48%, and 100%. In group C, the duration of response ranged between 5.13 and 9.46 months. In groups A and B, baseline plasma ctDNA sample sequencing identified prevalent alterations in\n                      <jats:italic>ERBB2<\/jats:italic>\n                      amplification (57%),\n                      <jats:italic>CCND1<\/jats:italic>\n                      amplification (22%), and mutations in\n                      <jats:italic>TP53<\/jats:italic>\n                      (49%),\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      (30%),\n                      <jats:italic>ESR1<\/jats:italic>\n                      (24%), and\n                      <jats:italic>GATA3<\/jats:italic>\n                      (14%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Imlunestrant in combination with trastuzumab\u2009\u00b1\u2009abemaciclib or pertuzumab presented a safety profile that was consistent with those of the partnered drugs. No new safety findings were observed. Furthermore, imlunestrant in combination with the partnered drugs demonstrated preliminary antitumor activity in patients with ER+\/HER2\u2009+\u2009ABC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier NCT04188548 (Registered 18 November 2019).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-025-02168-6","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T09:24:06Z","timestamp":1766309046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a\/1b EMBER study"],"prefix":"10.1186","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct04188548","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Manali","family":"Bhave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal L.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Lombard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik V.","family":"Giridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn T.","family":"Estrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monish Ram","family":"Makena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohi","family":"Ismail-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Beeram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"2168_CR1","unstructured":"National Cancer Institute. Cancer stat facts: female breast cancer subtypes. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"issue":"13","key":"2168_CR2","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2217\/fon-2020-0504","volume":"17","author":"C Kay","year":"2021","unstructured":"Kay C, Martinez-Perez C, Meehan J, Gray M, Webber V, Dixon JM, Turnbull AK. Current trends in the treatment of HR+\/HER2\u2009+\u2009breast cancer. Future Oncol. 2021;17(13):1665\u201381.","journal-title":"Future Oncol"},{"issue":"1","key":"2168_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","volume":"9","author":"M Pegram","year":"2023","unstructured":"Pegram M, Jackisch C, Johnston SRD. Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer. Npj Breast Cancer. 2023;9(1):45.","journal-title":"Npj Breast Cancer"},{"key":"2168_CR4","doi-asserted-by":"crossref","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014, 106(5).","DOI":"10.1093\/jnci\/dju055"},{"issue":"1","key":"2168_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1186\/s12885-021-08708-5","volume":"21","author":"MD Hackshaw","year":"2021","unstructured":"Hackshaw MD, Danysh HE, Henderson M, Wang E, Tu N, Islam Z, Ladner A, Ritchey ME, Salas M. Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review. BMC Cancer. 2021;21(1):967.","journal-title":"BMC Cancer"},{"key":"2168_CR6","doi-asserted-by":"crossref","unstructured":"M\u00fcller V, Bartsch R, Lin NU, Montemurro F, Pegram MD, Tolaney SM. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. Cancer Treat Rev 2023, 115.","DOI":"10.1016\/j.ctrv.2023.102527"},{"key":"2168_CR7","doi-asserted-by":"crossref","unstructured":"Gion M, Trapani D, Cort\u00e9s A, Valenza C, Lin N, Cort\u00e9s J, Curigliano G. Systemic therapy for HER2-Positive metastatic breast cancer: moving into a new era. Am Soc Clin Oncol Educational Book 2022(42):82\u201392.","DOI":"10.1200\/EDBK_351222"},{"issue":"8","key":"2168_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, et al. Pertuzumab, Trastuzumab, and docetaxel in HER2-Positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334.","journal-title":"N Engl J Med"},{"key":"2168_CR9","unstructured":": AFT-38 PATINA, Randomized A, Label O. Phase III trial to evaluate the efficacy and safety of Palbociclib\u2009+\u2009Anti-HER2 therapy\u2009+\u2009Endocrine therapy vs. Anti-HER2 therapy\u2009+\u2009Endocrine therapy after induction treatment for hormone Receptor-Positive (HR+)\/HER2-Positive Metastatic Breast Cancer [https:\/\/http:\/\/sabcs.org\/Portals\/0\/Documents\/PATINA_Abstract_12-11-24.pdf]"},{"issue":"3","key":"2168_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","volume":"21","author":"A Marra","year":"2024","unstructured":"Marra A, Chandarlapaty S, Modi S. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nat Reviews Clin Oncol. 2024;21(3):185\u2013202.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"2168_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","volume":"17","author":"K Goutsouliak","year":"2020","unstructured":"Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Reviews Clin Oncol. 2020;17(4):233\u201350.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"2168_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12885-021-09128-1","volume":"22","author":"Y Ozaki","year":"2022","unstructured":"Ozaki Y, Aoyama Y, Masuda J, Inagaki L, Kawai S, Shibayama T, Maeda T, Kurata M, Yoshida K, Saeki S, et al. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study. BMC Cancer. 2022;22(1):36.","journal-title":"BMC Cancer"},{"issue":"2","key":"2168_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(18)30001-9","volume":"19","author":"L Gianni","year":"2018","unstructured":"Gianni L, Bisagni G, Colleoni M, Del Mastro L, Zamagni C, Mansutti M, Zambetti M, Frassoldati A, De Fato R, Valagussa P, et al. Neoadjuvant treatment with trastuzumab and Pertuzumab plus Palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 2018;19(2):249\u201356.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2168_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","volume":"21","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763\u201375.","journal-title":"Lancet Oncol"},{"key":"2168_CR15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/PPA.S106629","volume":"10","author":"D Eek","year":"2016","unstructured":"Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, Shields AL. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609\u201321.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"2168_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1758834017711097","volume":"9","author":"K Boer","year":"2017","unstructured":"Boer K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2017;9(7):465\u201379.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"2168_CR17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1177\/08971900211012263","volume":"35","author":"JL Murdock","year":"2021","unstructured":"Murdock JL, Duco MR, Sharma SC, Reeves DJ. Embolia cutis medicamentosa (Nicolau Syndrome) secondary to intramuscular fulvestrant injection: A case report. J Pharm Pract. 2021;35(6):1034\u20138.","journal-title":"J Pharm Pract"},{"issue":"35","key":"2168_CR18","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1200\/JCO.23.02733","volume":"42","author":"KL Jhaveri","year":"2024","unstructured":"Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, et al. Imlunestrant, an oral selective Estrogen receptor Degrader, as monotherapy and in combination with targeted therapy in Estrogen receptor-Positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: phase Ia\/Ib EMBER study. J Clin Oncol. 2024;42(35):4173\u201386.","journal-title":"J Clin Oncol"},{"key":"2168_CR19","doi-asserted-by":"crossref","unstructured":"VandeKopple M, Mur C, Shen W, Marugan C, Capen A, Huber L, Castanares MA, Garcia-Tapia D, Mattioni B, Bastian J et al. 41P preclinical characterization of imlunestrant, an oral brain-penetrant selective Estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Open 2023, 8(1).","DOI":"10.1016\/j.esmoop.2023.101265"},{"issue":"2","key":"2168_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/10543406.2019.1636811","volume":"30","author":"M Liu","year":"2020","unstructured":"Liu M, Wang SJ, Ji Y. The i3\u2009+\u20093 design for phase I clinical trials. J Biopharm Stat. 2020;30(2):294\u2013304.","journal-title":"J Biopharm Stat"},{"key":"2168_CR21","doi-asserted-by":"publisher","first-page":"975463","DOI":"10.3389\/fonc.2022.975463","volume":"12","author":"R Ran","year":"2022","unstructured":"Ran R, Ma Y, Wang H, Yang J, Yang J. Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+\/HER2+) metastatic breast cancer: A review. Front Oncol. 2022;12:975463.","journal-title":"Front Oncol"},{"key":"2168_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ygyno.2024.10.006","volume":"191","author":"K Yonemori","year":"2024","unstructured":"Yonemori K, Boni V, Min KG, Meniawy TM, Lombard J, Kaufman PA, Richardson DL, Bender L, Okera M, Matsumoto K, et al. Imlunestrant, an oral selective Estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent\/advanced ER-positive endometrioid endometrial cancer: results from the phase 1a\/1b EMBER study. Gynecol Oncol. 2024;191:172\u201381.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2168_CR23","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38(12):1346\u201366.","journal-title":"J Clin Oncol"},{"issue":"20","key":"2168_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105\u201322.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2168_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discovery. 2023;22(2):101\u201326.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"2168_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-23-1209","volume":"30","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, Goel S, Nadal J, Denys H, Borrego MR, Litchfield LM, Liu J, Appiah AK, Chen Y, Andr\u00e9 F. Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus chemotherapy in HR+, HER2\u2009+\u2009Metastatic breast cancer patients. Clin Cancer Res. 2024;30(1):39\u201349.","journal-title":"Clin Cancer Res"},{"key":"2168_CR27","doi-asserted-by":"crossref","unstructured":"Neupane N, Bawek S, Gurusinghe S, Ghaffary EM, Mirmosayyeb O, Thapa S, Falkson C, O\u2019Regan R, Dhakal A. Oral SERD, a novel endocrine therapy for Estrogen Receptor-Positive breast cancer. Cancers (Basel) 2024, 16(3).","DOI":"10.3390\/cancers16030619"},{"issue":"Suppl 1","key":"2168_CR28","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","volume":"90","author":"JF Robertson","year":"2004","unstructured":"Robertson JF, Harrison M. Fulvestrant: pharmacokinetics and Pharmacology. Br J Cancer. 2004;90(Suppl 1):S7\u201310.","journal-title":"Br J Cancer"},{"issue":"1","key":"2168_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pmn.2010.03.002","volume":"14","author":"L Ozdemir","year":"2013","unstructured":"Ozdemir L, P\u03b9narc\u03b9 E, Akay BN, Akyol A. Effect of Methylprednisolone injection speed on the perception of intramuscular injection pain. Pain Manag Nurs. 2013;14(1):3\u201310.","journal-title":"Pain Manag Nurs"},{"issue":"1","key":"2168_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejon.2006.04.035","volume":"11","author":"AC Cox","year":"2007","unstructured":"Cox AC, Fallowfield LJ. After going through chemotherapy I can\u2019t see another needle. Eur J Oncol Nurs. 2007;11(1):43\u20138.","journal-title":"Eur J Oncol Nurs"},{"issue":"1","key":"2168_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jan.13818","volume":"75","author":"J McLenon","year":"2019","unstructured":"McLenon J, Rogers MAM. The fear of needles: A systematic review and meta-analysis. J Adv Nurs. 2019;75(1):30\u201342.","journal-title":"J Adv Nurs"},{"issue":"3","key":"2168_CR32","first-page":"e35748","volume":"15","author":"E Kut","year":"2023","unstructured":"Kut E, Menekse S. Retrospective evaluation of fulvestrant efficacy and clinical results in patients using fulvestrant. Cureus. 2023;15(3):e35748.","journal-title":"Cureus"},{"issue":"5","key":"2168_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, et al. Breast Cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"2168_CR34","doi-asserted-by":"crossref","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, Bajpai J, Barrios CH, Bergh J, Bergsten-Nordstr\u00f6m E et al. 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 2024, 76.","DOI":"10.1016\/j.breast.2024.103756"},{"issue":"9","key":"2168_CR35","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther. 2024;31(9):1283\u201391.","journal-title":"Cancer Gene Ther"},{"key":"2168_CR36","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O\u2019Shaughnessy J, Harbeck N, Carey LA et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2024, 0(0)."},{"issue":"10","key":"2168_CR37","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/OP.21.00172","volume":"17","author":"O Mart\u00ednez-S\u00e1ez","year":"2021","unstructured":"Mart\u00ednez-S\u00e1ez O, Prat A. Current and future management of HER2-Positive metastatic breast cancer. JCO Oncol Pract. 2021;17(10):594\u2013604.","journal-title":"JCO Oncol Pract"},{"issue":"28","key":"2168_CR38","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1200\/JCO.2017.76.7863","volume":"36","author":"M Rimawi","year":"2018","unstructured":"Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-Line trastuzumab plus an aromatase Inhibitor, with or without Pertuzumab, in human epidermal growth factor receptor 2-Positive and hormone receptor-Positive metastatic or locally advanced breast cancer (PERTAIN): A Randomized, Open-Label phase II trial. J Clin Oncol. 2018;36(28):2826\u201335.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2168_CR39","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-23-0117","volume":"29","author":"E Shagisultanova","year":"2023","unstructured":"Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, et al. Safety and efficacy of Tucatinib, Letrozole, and Palbociclib in patients with previously treated HR+\/HER2\u2009+\u2009Breast cancer. Clin Cancer Res. 2023;29(24):5021\u201330.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2168_CR40","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/annonc\/mdw622","volume":"28","author":"O Pagani","year":"2017","unstructured":"Pagani O, Klingbiel D, Ruhstaller T, Nol\u00e8 F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, et al. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22\/99. Ann Oncol. 2017;28(2):305\u201312.","journal-title":"Ann Oncol"},{"key":"2168_CR41","doi-asserted-by":"crossref","unstructured":"Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers (Basel) 2021, 13(12).","DOI":"10.3390\/cancers13122927"},{"issue":"22","key":"2168_CR42","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-20-0844","volume":"26","author":"E Ciruelos","year":"2020","unstructured":"Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Pare L, Escriva-de-Romani S, Manso L, Adamo B, Martinez E, et al. Palbociclib and trastuzumab in HER2-Positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial. Clin Cancer Res. 2020;26(22):5820\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2168_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, et al. The genomic landscape of Endocrine-Resistant advanced breast cancers. Cancer Cell. 2018;34(3):427\u2013e438426.","journal-title":"Cancer Cell"},{"issue":"10","key":"2168_CR44","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41588-019-0507-7","volume":"51","author":"L Angus","year":"2019","unstructured":"Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, Nik-Zainal S, Steenbruggen TG, Tjan-Heijnen VCG, Labots M, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019;51(10):1450\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"2168_CR45","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/s41467-021-22605-2","volume":"12","author":"B Kingston","year":"2021","unstructured":"Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, Swift C, Kilburn LS, Kernaghan S, Moretti L, et al. Genomic profile of advanced breast cancer in Circulating tumour DNA. Nat Commun. 2021;12(1):2423.","journal-title":"Nat Commun"},{"issue":"3","key":"2168_CR46","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, Walch H, Chatila WK, Madupuri R, Kundra R, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022;185(3):563\u2013e575511.","journal-title":"Cell"},{"issue":"10","key":"2168_CR47","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573\u201383.","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"2168_CR48","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","volume":"34","author":"C Fribbens","year":"2016","unstructured":"Fribbens C, O\u2019Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, et al. Plasma ESR1 mutations and the treatment of Estrogen Receptor-Positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02168-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02168-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02168-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:32:53Z","timestamp":1781623973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02168-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2168"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02168-6","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethical\/institutional review boards and conducted according to the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice Guideline, and applicable regulatory requirements. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Manali Bhave: Consulting or Advisory Role: Daiichi Sankyo\/AstraZeneca, Merck, Lilly, Pfizer, Gilead SciencesKomal L. Jhaveri: Consulting or Advisory Role: Novartis, Pfizer, AstraZeneca, Jounce Therapeutics, Synthon, Intellisphere, Bristol Myers Squibb, Genentech, AbbVie, Lilly, BluePrint Medicines, Seagen, Daiichi Sankyo, Biotheranostics, Sun Pharma Advanced Research Company, Taiho Oncology, Sanofi, Gilead Sciences, Eisai, Bicycle Therapeutics, Scorpion TherapeuticsResearch Funding: Novartis (Inst), Genentech (Inst), Debiopharm Group (Inst), ADC Therapeutics (Inst), Pfizer (Inst), Novita Pharmaceuticals (Inst), Clovis Oncology (Inst), Lilly (Inst), Zymeworks (Inst), Immunomedics (Inst), Puma Biotechnology (Inst), VelosBio\/Merck (Inst), AstraZeneca (Inst), Context Therapeutics (Inst), Scorpion Therapeutics (Inst), Eisai (Inst), Rayzebio (Inst)Blueprint Medicines (Inst)Travel, Accommodations, Expenses: Taiho Pharmaceutical, Jounce Therapeutics, Pfizer, AstraZeneca, Intellisphere, Lilly, Gilead Sciences, Genentech\/RochePeter A. Kaufman:Stock and Other Ownership Interests: Amgen, Johnson & Johnson\/JanssenHonoraria: Lilly, Eisai, AstraZenecaConsulting or Advisory Role: Polyphor, Roche\/Genentech, Lilly, Eisai, Macrogenics, Pfizer, Merck, AstraZeneca, Sanofi, Seagen, Sermonix PharmaceuticalsSpeakers\u2019 Bureau: LillyResearch Funding: Eisai (Inst), Polyphor (Inst), Lilly (Inst), Novartis (Inst), Pfizer (Inst), Sanofi (Inst), Zymeworks (Inst), Sermonix Pharmaceuticals (Inst)Expert Testimony: SeagenTravel, Accommodations, Expenses: Lilly, Polyphor, SeagenPhilippe Aftimos: Honoraria: Synthon, Roche, Gilead SciencesConsulting or Advisory Role: Macrogenics, Boehringer Ingelheim, Novartis, Amcure, Roche, Amgen, Servier, G1 Therapeutics, Radius Health, Deloitte, Menarini, Gilead Sciences, Incyte, Lilly, OlemaResearch Funding: Roche (Inst)Travel, Accommodations, Expenses: Amgen, MSD Oncology, Roche Belgium, Pfizer, Daiichi Sankyo\/AstraZeneca, Gilead SciencesJanine Lombard: Honoraria - AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Novartis Consulting or Advisory Role \u2013 AstraZeneca Travel, Accommodations, Expenses \u2013 LillyKarthik V. Giridhar: Research funding: Guardant Health; Advisory board: AstraZeneca, Eli Lilly and Company, Novartis, Neogenomics, TerSera Therapeutics, Puma Biotechnology. Attending meeting and\/or travel: Eli Lilly and Company, Grail Inc.Seock-Ah Im: Consulting or Advisory Role: AstraZeneca, Novartis, Roche\/Genentech, Eisai, Pfizer, Amgen, Hanmi, Lilly, MSD, Daiichi Sankyo Research Funding: AstraZeneca (Inst), Pfizer (Inst), Roche\/Genentech (Inst), Daewoong Pharmaceutical (Inst), Eisai (Inst), Boryung Pharmaceuticals (Inst) Other Relationship: RocheCynthia X. Ma: Consulting or Advisory Role: Novartis, AstraZeneca, Biovica Inc, Olaris, Gilead Sciences, Pfizer, Lilly, Tempus, Genzyme, Tersera, Stemline Therapeutics, Daiichi Sankyo\/AstraZeneca, Regor Therapeutics Group, Danatlas, Merck Research Funding: Pfizer (Inst), Puma Biotechnology (Inst) Kuo-Ting Lee: no conflicts to disclose.Sung-Bae Kim: Stock and Other Ownership Interests: Genopeaks Honoraria: Daehwa Pharmaceutical, LegoChem Biosciences, Kalbe Farma Consulting or Advisory Role: Lilly (Inst), AstraZeneca, Daehwa Pharmaceutical, ISU Abxis, BeiGene, Daiichi Sankyo\/AstraZeneca, OBI Pharma, Ensol Biosciences Research Funding: Genzyme (Inst)Yujia Li: Employment: Lilly, Memorial Sloan-Kettering Cancer Center Stock and Other Ownership Interests: Lilly, Pfizer, Illumina Travel, Accommodations, Expenses: LillyEunice Yuen: Employment: Lilly Stock and Other Ownership Interests: LillyShawn T. Estrem: Employment: Lilly Stock and Other Ownership Interests: LillyBastien Nguyen: Employment: Loxo\/LillyMonish Ram Makena: Employment: Loxo\/LillyRoohi Ismail-Khan: Employment: Eli Lilly\/Loxo Oncology Stock and Other Ownership Interests: LillyJoohyuk Sohn: Stock and Other Ownership Interests: Daiichi Sankyo Research Funding: MSD (Inst), Roche (Inst), Novartis (Inst), Lilly (Inst), Pfizer (Inst), Daiichi Sankyo (Inst), AstraZeneca (Inst), GlaxoSmithKline (Inst), Sanofi (Inst), Boehringer Ingelheim (Inst), Seagan (Inst), Qurient (Inst), Dragonfly Therapeutics (Inst), Eikon (Inst), Gilead Sciences (Inst), Celcuity (Inst), Bristol Myers Squibb (Inst), HLB Life Science (Inst), Sermonix Pharmaceuticals (Inst), Olema Oncology (Inst), Hanmi Pharm (Inst), Ildong Pharmaceutical (Inst), Samyang Holdings (Inst)Muralidhar Beeram: Honoraria: Genentech (Inst), Johnson & Johnson (Inst) Consulting or Advisory Role: Novartis, Bayer, Merck, Seagen Speakers\u2019 Bureau: Genentech (Inst), Merck (Inst), Bristol Myers Squibb (Inst) Research Funding: Lilly (Inst), Zymeworks (Inst), Mersana (Inst), Phoenix Molecular Designs (Inst), Merrimack (Inst), Agios (Inst), Puma Biotechnology (Inst), Merck (Inst), AstraZeneca (Inst) Travel, Accommodations, Expenses: Genentech, Merck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}